Runx1 is required for definitive hematopoiesis and is well known for its frequent chromosomal translocations and point mutations in leukemia. Runx1 regulates a variety of genes via Ets1 activation on an Ets1Runx1 composite DNA sequence. The structural basis of such regulation remains unresolved. To address this problem, we determined the crystal structure of the ternary complex containing Runx1 1-242 and Ets1 296-441 bound to T-cell receptor alpha (TCRa) enhancer DNA. In the crystal, an Ets1-interacting domain of Runx1 is bound to the Ets1 DNA-binding domain and displaced an entire autoinhibitory module of Ets1, revealing a novel mechanism of Ets1 activation. The DNA-binding and transcriptional studies with a variety of structure-guided Runx1 mutants confirmed a critical role of direct Ets1Runx1 interaction in Ets1 activation. More importantly, the discovered mechanism provides a plausible explanation for how the Ets1Runx1 interaction effectively activates not only a wild-type Ets1, but also a highly inhibited phosphorylated form of Ets1.
INTRODUCTION
Regulation of gene expression in eukaryotes is an extremely complex process. 1 Cis-regulatory sequences on promoters and enhancers of target genes facilitate the cooperative assembly of transcriptional regulatory complexes. 1 In addition, multiple signaling cascades contribute to more elaborate regulation of gene expression by post-translational modifications of transcriptional factors (TFs). 2 In spite of recent breakthroughs in high-resolution methods for studies of TFs genomics, the details of TF partnerships, especially with contributions of post-translational modifications, are poorly understood due to insufficient structural data. 1 Ets1Runx1 partnership provides a perfect basis for filling the gap. The two TFs regulate T-cell receptor alpha (TCRa) and a variety of other genes via binding to a composite Ets1Runx1 sequence. [3] [4] [5] [6] [7] Ets1 transcription factor participates in embryonic development, lymphoid differentiation, proliferation, apoptosis and angiogenesis. 8 It is amplified and rearranged in a variety of cancers. 9 DNA binding of Ets1 is regulated by an inhibitory serinerich region (SRR) and inhibition regulatory module (IRM) flanking its DNA-binding Ets domain (ED) (Figure 1a ). 10 IRM comprises inhibitory helices HI1 and HI2 N-terminal to the ED and H4 and H5 C-terminal to the ED. 11, 12 The IRM and the SRR interact with the ED, resulting in a 40-fold reduction in DNA-binding affinity. 13 DNA binding of Ets1 is also regulated by a Ca 2 þ signaling-mediated phosphorylation of the serines in SRR. [13] [14] [15] Partner proteins activate Ets1 and among them is a Runx1 transcription factor. Runx1 acts by targeting the IRM of Ets1 via direct physical interaction between the two proteins. 4, 10, 16, 17 Runx1 is required for definitive hematopoiesis and is well known for its frequent chromosomal translocations and point mutations in leukemia. 18 DNA binding of Runx1 is autoinhibited by sequences flanking its DNA-binding Runt domain (RD) (Figure 1a ). 16, 17 Core binding factor b (CBFb) binds RD and enhances Runx1 DNA binding without interacting with DNA. 19 In contrast, the Runx1Ets1 cooperation requires the binding of both factors to a composite Runx1Ets1 DNA motif. Genome-wide analysis for the co-occupancy of Ets1 and Runx1 revealed such composite motifs in a number of genes. 6, 7 Among the well-characterized motifs is a GGATGTGG motif of TCRa and TCRb gene enhancers. [3] [4] [5] In our previous studies, we revealed an allosteric mechanism of Runx1 activation by CBFb. 20 Here, we expand our studies to the mechanism of Ets1 activation by Runx1.
MATERIALS AND METHODS

Construction of plasmids, expression and purification
The coding region for different Runx1 constructs (Runx1 1-242 , Runx1 48-214 , Runx1 1-214 , Runx1 and Runx1 48-242 ) were PCR amplified from pVL1392-AML1.FL plasmid and cloned into pET3a vector (Novagen, Chicago, IL, USA). The resulting constructs were expressed in E. coli strain Rosetta-2(DE3) at 18 1C for 16 h following induction with 0.3 mM isopropyl b-D-thiogalactopyranoside at A 600 ¼ 1. Cells were harvested and resuspended in buffer A (20 mM Tris-HCl pH 7.2, 1 M NaCl, 1 mM ETDA, 10 mM b-mercaptoethanol and 10% glycerol) and lysed with an EmulsiFlex-C5 homogenizer (Avestin, Ottawa, ON, Canada). Polyethyleneimine was added to the supernatant at a final concentration of 0.07% and pellet was removed by centrifugation. Proteins were enriched by ammonium sulfate precipitation at 30% saturation. Each pellet was resuspended in buffer A 100 containing 100 mM NaCl and dialyzed against the same buffer for 3 h. The proteins were purified using HiTrap SP HP (GE Healthcare, Pittsburg, PA, USA) followed by HiTrap Heparin HP column (GE Healthcare). Pooled fractions were diluted to half with 1.5 M ammonium sulfate in buffer A 100 and purified using HiTrap Phenyl HP column (GE Healthcare). Purity of fractions was checked by SDS-PAGE and stored at À 80 1C.
Single and multiple site mutagenesis protocol 21 was used to create point mutants of Runx1. Mutations were first introduced in full-length Runx1 plasmid (pCDN3-Myc3-Runx1) and the resultant mutants were further subcloned in vector pET3a. All mutants were verified by DNA sequencing and were expressed and purified as described above.
Ets1 280-441 was purified according to reported protocols. 22 Cloning, expression and purification conditions for Ets1 296-441 were similar to those of the Ets1 280-441 protein, except supernatant obtained from 50% ammonium sulfate saturation was used for purification. Coding region for Ets1 276-441 was cloned in a ligation-independent vector in fusion with affinity His 6 -tagged small ubiquitin-related modifier (SUMO) protein. 23 His 6 -SUMO-Ets1 276-441 was expressed in E. coli strain BL21(DE3) at 37 1C for 5 h following induction with 0.5 mM isopropyl b-D-thiogalactopyranoside at A 600 ¼ 0.5. Harvested cells were resuspended in 20 mM Tris-HCl pH 7.2, 1 M NaCl, 1 mM b-mercaptoethanol, 5 mM Imidazole and 12% glycerol. Initial treatment for purification of His 6 -SUMO-Ets1 276-441 was similar to other Ets1 constructs except the pellet obtained by 40-65% of ammonium sulfate fractionation was used for purification. The pellet was resuspended in 20 mM Tris-HCl pH 7.2, 750 mM NaCl, 1 mM b-mercaptoethanol, 5 mM Imidazole and 5% glycerol and purified by HisTrap HP column (GE Healthcare). His 6 -SUMO was cleaved with His 6 -tagged dtUD1 (doubletagged UD1) protease that was added to protein at 1/5000 mass ratio and incubated for 3 h at 4 1C before loading onto Ni-IDA column (Bio-Rad, Hercules, CA, USA). Flow through from the column containing Ets1 276-441 was collected and stored at À 80 1C.
Ets1 276-441 was phosphorylated using the published protocol. 13 Peak fractions were pooled and analyzed by SDS-PAGE and MALDI TOF/TOF ( Supplementary Figure 1 ). CaMKIIa used in the kinase reaction was purified according to reported protocol. 24 Crystallization and diffraction data collection Double-stranded TCRa enhancer DNA (TCRa) was prepared by annealing synthetic oligonucleotides 5 0 -GGAAGCCACATCCTCT-3 0 and 5 0 -CAGAGG ATGTGGCTTC-3 0 . Oligonucleotides were purified using Mono Q 5/50 GL column (GE Healthcare) and annealed by heating to 95 1C for 5 min and cooling gradually to room temperature. Annealed DNA was purified using Mono Q 5/50 GL. The DNA solution was desalted, dried and dissolved in 10 mM Tris-HCl pH 7.5. For Runx1 1-242 Ets1 296-441 TCRa complex preparation, the frozen Runx1 1-242 and Ets1 296-441 samples were thawed on ice, dialyzed against 10 mM Tris-HCl pH 7.5 and 20 mM DTT buffer and concentrated using Millipore (Chicago, IL, USA) Ultrafree centrifugal devices to 7 and 10 mg/ml, respectively. At first, a Runx1 1-242 TCRa was prepared and then Ets1 296-441 was added to reach an equal molar ratio of components. The ternary complex was concentrated up to 7 mg/ml. The state of sample aggregation at every step was monitored by dynamic light scattering using DynoPro (Wyatt Technology, Santa Barbara, CA, USA). The Runx1 48-214 Ets1 296-441 TCRa complex was prepared in a similar way.
All crystallization screenings were performed by sitting-drop vapordiffusion method using Natrix screen kit from Hampton Research (Aliso Viejo, CA, USA). Runx1 1-242 Ets1 296-441 TCRa produced squarebipyramid and plate-shaped crystals in the same drop within 48 h. Initial crystallization condition was further optimized as 100 mM KCl, 15 mM magnesium chloride hexahydrate, 25 mM MES pH 5.6, 14% v/v PEG MME 550 and 6% v/v glycerol ( Supplementary Figure 2a ). The size of either crystal was improved by macroseeding after 12 h of equilibration. Growth of the seeded crystals was completed in 10 days ( Supplementary Figures 2b  and c) . The crystals were cryoprotected in reservoir solutions containing additions of 3% v/v PEG MME 550 and 18% v/v of ethylene glycol for square-bipyramid crystals and 15% v/v of glycerol for plate-shaped crystals.
The Runx1 48-214 Ets1 296-441 TCRa also produced two types of crystals from the same drop of Natrix crystal screen, one deformed cube type and another rod type. The optimum growth of crystals was achieved from a 2.5% w/v PEG 4000, 5 mM magnesium chloride hexahydrate, 25 mM MES pH 5.6 and 5% v/v glycerol ( Supplementary Figures 2d and e ). The cryoprotectant for deformed cube crystals contained additions of 2.5% w/v PEG 4000, 12.5% v/v PEG 200 and 11.5% v/v ethylene glycol. The rodshaped crystals diffracted poorly to 7 Å resolution and were excluded from further studies.
The diffraction data sets were collected using synchrotron radiation at the Advanced Photon Source on the Northeastern Collaborative Access Team beamline BL24ID-E. To minimize the radiation damage, each complete data set was obtained from one crystal exposed at several different positions. All intensity data were indexed, integrated and scaled using the HKL2000 program package 25 (Table 1) .
Structure determination and refinement
The structure of deformed cube crystal was determined by the molecular replacement method starting with the coordinates of ED from Ets1 structure (PDB code 1gvj) 26 and RD from Runx1DNA structure (PDB code 1hjc). 20 The asymmetric unit contained two molecules of Runx1 48-214 Ets1 296-441 TCRa. Addition of a DNA molecule and major manual rebuilding of the initial model was performed with the TURBO-FRODO software (Aix-Marseille University, Marseille, France). Application of zonal scaling 27 and bulk solvent correction improved the quality of electron density maps, enabling Ets1-interaction domain (EID) of Runx1 to be clearly traced and most of the protein side chains to be well fitted. A model was refined using standard protocols. Non-crystallographic two-fold symmetry restraints for backbone atoms were applied during the refinement. The structure determination of square-bipyramid and plate-shaped crystals was similar to that of cube crystal, but without non-crystallographic two-fold symmetry restraints. The final refinement statistics for all three structures are provided in Table 1 . CNS version 1.1 (Yale University, New Haven, CT, USA) was used for all crystallographic computing. 28 The figures with electron density maps were prepared with the TURBO-FRODO software and all remaining figures displaying the protein structures were prepared with the PyMol software from Delano Scientific (Palo Alto, CA, USA).
Surface plasmon resonance experiments
Surface plasmon resonance (SPR) studies were performed using Biacore 3000 biosensor system (GE Healthcare) at 25 1C. A 26-bp double-stranded DNA corresponding to TCRa enhancer sequence 5 0 -AAGCAGAAGCCA-CATCCTCTGGAAAG-3 0 with a covalently linked biotin at 5 0 end was captured on SA sensor chip (GE Healthcare) at B100 response units. Just before initiating the experiment, each protein or its mutants were purified through gel filtration column (Superose 12 10/300 GL; GE healthcare) to remove protein aggregates if present. Kinetic runs were conducted at 30 ml/min to eliminate mass transport and rebinding artifacts. As analytes, each protein or its mutants were diluted serially in the running buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 2 mM MgCl 2 , 2 mM DTT and 0.005% Tween-20) to concentrations shown in Supplementary Tables 1-3 and injected over the immobilized ligand surface for 120 s. For experiments where the binding of one protein was measured in the presence of another, 100 nM of second protein was included in running buffer. Dissociation of analytes was then measured by injecting running buffer or running buffer containing protein. The surface was 'regenerated' with a pulse of 1 M NaCl at the end of each cycle. Duplicate injections of the same concentration in each experiment were superimposable, demonstrating no loss of activity after regenerating the surface. Buffer injection subtracted graphs were analyzed with BIA evaluation version 4.1 (GE Healthcare) using a non-linear least squares method to obtain the association and dissociation rate constants (k a and k d , respectively). For these calculations, the global fitting of the association and dissociation phases of the response curves using a 1:1 binding model was applied. The fittings were considered as satisfactory if w 2 o2. The equilibrium dissociation constants (K D ) were calculated from the equation K D ¼ k d /k a . Standard deviations were calculated from three experiments.
Transient transfection assays
A 98-bp nucleotide sequence from minimal human TCRa enhancer (12-109) 4 was cloned upstream to the SV40 promoter in pGL3-Basic vector (where the SV40 promoter is inserted upstream to Luciferase gene). pCDN3-Myc3-Runx1/mutants and pCMV-Tag2a-FlagEts1 were used as an expression vector for Runx1 and Ets1, respectively. Thr286 of pEGFP-C1-CamKIIa was mutated to Asp for constitutive enzymatic activity. 24 Expression of constitutively active CamKIIa was confirmed by observing the GFP fluorescence in the cells.
Stock cultures of 293 T cells were maintained as described earlier. 22 For transcriptional assays, 293 T cells were seeded at 50 000 cells per well of 6-well plates and transfected in duplicate the following day using X-treme gene HP DNA transfection reagent following the manufacturer's protocol. In addition to 2 mg of the promoter/reporter construct, the cells were co-transfected with 25 ng of pTK-RL (Promega, San Luis Obispo, CA, USA) to normalize for any differences in transfection efficiency. Expression levels of wild-type Ets1 and Runx1 as well as Runx1 mutants were determined by transiently transfecting 293 T cells separately with expression vector harboring the construct for the corresponding protein. To test cooperativity in binding of these proteins, co-transfection of Ets1 and Runx1/mutants was performed. Equal amounts of total DNA in each transfection were maintained by adding empty vector CMV5 as needed. Luciferase activity was measured 48 h after transfection using the Dual-Luciferase Reporter Assay System (Promega).
RESULTS
Crystal structures
We crystallized and solved the structures of a ternary complex of Runx1 (residues 1-242), Ets1 (296-441) and 16 base pair DNA fragment of TCRa enhancer (Runx1 1-242 Ets1 296-441 TCRa) in square-bipyramid and plate crystal forms and also Runx1 48-214 Ets1 296-441 TCRa in a deformed cube form (Table 1 ). In all three structures, the ED and the RD are bound to respective binding sites positioned opposite relative to each other (Figure 1b ; Supplementary Figures 3a-c) . Distributions of temperature factors in these complexes are shown in Supplementary Figures 3d-f . The excellent electron density maps of Runx1 48-214 Ets1 296-441 TCRa ( Supplementary Figures 4a and b ) unambiguously revealed the structure of residues 189-205 from an EID of Runx1, which includes the helix a1 (194) (195) (196) (197) (198) (199) (200) (201) (202) (203) . In addition to helix a1, the main-chain tracing of EID helix a2 (204-211) was clearly defined in square-bipyramid Runx1 1-242 Ets1 296-441 TCRa crystal ( Supplementary Figure 4c) . Explanation of the crystal packing effects resulting in disorder of Runx1 Phe194 side chain in squarebipyramid Runx1 1-242 Ets1 296-441 TCRa crystal, in disorder of EID a2 in Runx1 48-214 Ets1 296-441 TCRa crystal and in disorder of an entire EID in Runx1 1-242 Ets1 296-441 TCRa plate crystal is provided in Supplementary Figure 5 .
Runx1 EID interactions with Ets1 and DNA The Runx1 helix a1 is packed on ED parallel to H1 of Ets1, whereas Runx1 a2 is packed parallel to DNA (Figure 1b) . EID interaction buries a total surface area of 1146 Å 2 . The EIDEts1 interactions are dominated by hydrophobic amino-acid residues (Supplementary Table 4 ). The EID Phe194, Leu198 and Leu201 side chains are packed into the wide hydrophobic depression at Ets1 surface (Figure 2a ). In addition, EID Arg197 forms a direct hydrogen bond with backbone oxygen of Ets1 Leu422 (Figure 2a ). At the EIDDNA interface, a positively charged area of EID formed by Arg205, Arg206 and Arg210 is positioned against the negatively charged phosphates of DNA (Figure 2b) providing the long-range proteinDNA electrostatic interactions that further stabilize the structure of EIDEts1DNA. In addition, an Arg205 side chain electron density in Runx1 48-214 Ets1 296-441 TCRa crystal ( Supplementary Figure 4a) indicates a direct interaction of Arg205 with DNA backbone (Supplementary Figure 6 ).
Runx1 EID displaces the IRM of Ets1
The structures of ED and RD and their modes of DNA recognition in Runx1 1-242 Ets1 296-441 TCRa complex are consistent with the previously reported crystal structures ( Supplementary  Figure 7) . 22, 26, [29] [30] [31] [32] [33] However, a prominent difference exists in folding of IRM within Ets1 that is bound to DNA. The HI1 is unfolded in Ets1Pax5DNA and is folded in (Ets1 dimer)DNA, while HI2 is folded in both complexes ( Supplementary Figure 8) . In contrast, the entire inhibitory module of Ets1, including IRM, is disordered in Runx1 1-242 Ets1 296-441 TCRa. Comparison of Ets1EID structure from our ternary complex with the solution structure of autoinhibited Ets1 (ref. 12) shows an overlapping of the space occupied by EID of Runx1 and IRM of Ets1 (Figure 2c ). This demonstrates that EID of Runx1 displaces IRM of Ets1. Thus, the crystal structure of Runx1 1-242 Ets1 296-441 TCRa provides a novel mechanism of Ets1 cooperative binding to DNA in which the EID of DNA-bound Runx1 displaces the IRM of Ets1 and consequently disrupts the inhibitory function of the residues N-terminal to IRM (Figure 3 ). This is consistent with previously reported constitutively active mutants of Ets1 that disrupt the IRM docking to ED and also lead to Ets1 activation. 15 Runx1 EID contributes to cooperative binding of Ets1 to DNA To validate the functional relevance and specificity of the observed EIDED and EIDDNA interactions, we decided to prepare a variety of Runx1 deletions and mutations and analyze their DNA binding by SPR.
First, we tested DNA binding of Runx1 proteins (Supplementary Table 1 ). Runx1 1-214 exhibited sevenfold lower K D of 0.47 nM than Runx1 1-242 K D of 3.3 nM. These data confirm the presence of autoinhibitory sequences C-terminal to 214. 17 However, deletion of 47 residues from N-terminus of Runx1 had little impact on DNA (Figure 4a ; Supplementary Table 2 ). K D of Ets1 is 30 nM, however in the presence of DNA-bound Runx1 1-242 the DNA-binding activity of Ets1 280-441 is enhanced 11.5-fold (K D ¼ 2.6 nM). C-terminal truncation of Runx1 up to residue 214 (Runx1 1-214 ) had minimal effect on Ets1 activation, which is consistent with the disordered state of residues 213-242 in crystal. In contrast, further C-terminal truncation up to residue 190 (Runx1 ) resulted in a complete loss of Ets1 activation (K D ¼ 34.4 nM). This series of mutants maps the region between 190 and 214 as essential for cooperativity with Ets1, as previously shown. 17 The absence of Ets1 activation by Runx1 confirms that, in spite of partial overlapping of Ets1 and Runx1 binding sites, the cooperation through DNA effect does not occur and points to a direct participation of EID in the cooperative binding of Ets1 to the TCRa enhancer. The absence of cooperation through DNA conformational changes is consistent with the studies by Goetz et al 10 using a different approach. To eliminate through DNA effect in their electrophoretic mobility shift assays, these investigators used DNA duplexes containing a nick on one strand between the Runx1 and Ets1 binding sites. They found that Runx1 retained Ets1 activation even with a nicked DNA and concluded the absence of Runx1Ets1 cooperation through changes in DNA conformation. 10 In combination, our biochemical and structural data demonstrate that a direct protein interaction explains the cooperative DNA binding between these two factors.
Interaction of Runx1 EID with both Ets1 and DNA is highly specific We analyzed the effect of EID point mutations in its Ets1-and DNA-interacting interfaces (Figure 4a ; Supplementary Table 2 ). We mutated each of three hydrophobic Ets1-interacting amino-acid residues Phe194, Leu198 and Leu201 to Ala in Ets1-interacting helix a1 and also prepared double and triple Ala mutants. Furthermore, we introduced a kink in helix a1 by a Ser199Pro mutation. Any of these mutations destabilize EIDEts1 interaction and result in loss of Ets1 DNA binding activation. To evaluate the contribution of electrostatic interactions between the EID helix a2 and DNA, we prepared the Arg205Glu mutant. As a result, the positive charge reduction in helix a2 prevented the cooperative DNA binding by Ets1. In summary, SPR experiments confirm that interaction of EID with both Ets1 and DNA is highly specific and necessary for activation of Ets1 DNA binding.
Concerted binding of Runx1 and Ets1 to TCRa enhancer Order of addition DNA-binding experiments indicate that Runx1 and Ets1 form a ternary complex with TCRa enhancer in a highly concerted manner, consistent with previous observations. 17 First, Runx1 binds DNA, and only then does EID recruit Ets1 by binding to ED and displacing the IRM of Ets1. As a consequence, Ets1 becomes active by over 11-fold. In case of reverse order of addition experiments, the TCRa enhancer-bound Ets1 was not capable of Runx1 stimulation ( Supplementary Table 1 ). SPR experiments also show that the addition of CBFb, a heterodimeric partner of Runx proteins, does not enhance Ets1 recruitment (Figure 4a ; Supplementary Table 2 ). This is in line with the model of Ets1Runx1CBFbTCRa quaternary complex revealing the absence of physical interaction between CBFb and Ets1 ( Supplementary Figure 9) . A similar role of CBFb and 'order of addition' effect was observed with Runx1 and Ets1 binding to a socalled SC1/core DNA having different spacing between Runx1 and Ets1 binding sites. 10, 17 The Runx1Ets1 cooperative action in two different composite sites points to a flexibility of the linker between the RD and the EID, which is consistent with the disorder of this linker in our crystals.
Runx1 overcomes an inhibitory effect of Ets1 phosphorylation Ca 2 þ -dependent phosphorylation of serines in the flexible inhibitory region of Ets1 was found to further stabilize the inhibitory conformation and consequently reinforce Ets1 autoinhibition up to 50-fold. 13, 15 To test whether Runx1 is also capable of overcoming Ets1 autoinhibition after the phosphorylation, we phosphorylated Ets1 276-441 at two critical sites, Ser282 and Ser285 (Ets1 276-441 **, Figure 1a ; Supplementary Figure 1 ). SPR experiments revealed a 14-fold reduction in Ets1 276-441 DNA-binding affinity after the phosphorylation (Figure 4b ; Supplementary  Table 3 ). Remarkably, in the presence of prebound Runx1 1-242 or Runx1 1-242 CBFb complex, the DNA binding of Ets1 276-441 ** was dramatically enhanced and reached the same order (only about 3-fold less) as a wild-type Ets1 276-441 . To the contrary, Ets1 276-441 ** DNA binding was not enhanced in the presence of prebound Runx1 lacking EID. To confirm that EID is responsible for the enhancement of Ets1 276-441 ** DNA binding, we evaluated the effect of single Ser199Pro and double Leu198Ala/Leu201Ala mutations in a2 helix of EID. Both mutations disrupt EIDEts1 interaction and result in the loss of Ets1 276-441 ** DNA binding enhancement. These experiments confirm that Runx1 EID overcomes an inhibitory effect of Ets1 phosphorylation by displacing the IRM of Ets1.
Synergistic trans-activation of TCRa gene by Runx1Ets1 cooperation Furthermore, we examined the effect of Runx1 and Ets1 cooperative binding and trans-activation of TCRa gene enhancer fragment by transient transfection assay. To determine the impact of Ets1 phosphorylation, the experiments were also performed in the presence of constitutively active CaMKIIa. Synergistic transactivation of TCRa gene enhancer was observed both with wildtype and with phosphorylated Ets1. However, disrupting EIDEts1 interaction with Runx1 mutations eliminated the synergy. The results of the SPR (Figure 4b ) and transient transfection (Figure 4c ) experiments provide additional support for a mechanism of Ets1 activation that is based on displacement of an entire N-terminal inhibitory module of either wild type or phosphorylated Ets1 by EID of DNA-bound Runx1 (Figure 3 ).
DISCUSSION
Comparison of Runx1Ets1 cooperation with other modes of Ets proteins cooperation
Analysis of Runx1Ets1TCRa structure and other Ets1 ternary complex crystal structures shows that Ets1 can adopt a variety of different mechanisms for formation of high-order complexes on DNA. For example, Ets1 binds poorly to suboptimal 5 0 -GGAG-3 0 sequence on mb-1 promoter, however, in the presence of Pax5 it EID of DNA-bound Runx1 is exposed and disordered. Upon approaching Ets1, EID of Runx1 binds to ED and DNA by forming helices a1 and a2, and displacing both IRM helices HI1 and HI2. This results in disorder of IRM and destabilization of SRR inhibitory confirmation, producing a fully active Ets1. Similar to activation of wild-type Ets1, Runx1 also fully activates the phosphorylated form of Ets1. In both panels, the red stars indicate the presence of phosphorylated serines in SRR.
Structural basis of Ets1 activation by Runx1 T Shrivastava et al binds mb-1 promoter with high affinity. 34 Crystal structure of Pax5Ets1mb-1 revealed a direct interaction between DNAbinding domains of Pax5 and Ets1 that altered the DNA-binding surface of Ets1, mainly by conformational switch of its Tyr395 side chain (Figure 5a ). 29, 30 Another example is Ets1 cooperative binding to stromelysin-1 promoter containing palindromic head-to-head Ets-binding sites separated by four base pairs. 35 Crystal structure shows that cooperative binding to stromelysin-1 promoter is facilitated by DNA-mediated homodimerization of Ets1 (Figure 5b ). 22, 36 Recently, we reported the crystal structure of Ets1 in complex with TCRa enhancer DNA. 26 In this structure, Ets1 binds as a homodimer to parallel pieces of dsDNA having Etsbinding sites with opposite orientation (Figure 5c ). 26 Observation of additional intermolecular Ets1DNA interactions within this complex (Figure 5c ) indicates that Ets1 binding is cooperative. 26 Among these Ets1 complexes, the most dramatic effect on Ets1 inhibitory IRM-SRR sequences we can see is in Runx1Ets1TCRa where an IRM is fully disordered. In the Pax5Ets1mb-1, only HI2 of IRM remains bound to ED; however, HI1 is unfolded and partially structured. HI2 remains well folded also in the DNAbound Ets1 homodimers. Moreover, an ED in these structures also favors the binding of HI1 from a symmetry-related molecule.
It is also interesting to compare mechanism of Ets1 activation by Runx1 with the mechanism of activation of another Ets family member, SAP1. Like Ets1, DNA binding of SAP1 is also autoinhibited. SAP1 B-box sequences that are attached by a flexible linker to the C-terminal of ED participate in autoinhibition by interacting with ED. However, SAP1 becomes active and binds to c-fos serum response element (SRE) in the presence of serum response factor (SRF). 37, 38 The crystal structure of SAP1SRFSRE shows how an autoinhibition of SAP1 was relieved by switching the B-box from ED to the surface of SRF (Figure 5d ). 39 Furthermore, the cooperative binding is enforced by direct interaction between DNA-binding domains of SAP1 and SRF. 39, 40 The crystal structures highlight the differences between Ets1 activation by Runx1 and SAP1 activation by SRF. In case of Ets1, binding of Runx1 EID to ED disrupts the autoinhibitory IRM-SRR packing. However, in case of SAP1 activation, its autoinhibitory B-box is moved away from ED by interacting with SRF.
CONCLUSION
Protein-protein interactions and post-translational modifications have an important role in combinatorial regulation of transcription. During different stages of regulation the same transcription factor may interact with different sets of partners. For example, studies of Runx1 partners during different stages of megakaryocytic differentiation revealed its interactions with either GATA, or AP-1 or Ets proteins. 41 Such a dynamic nature of Runx1 interactions and TFs in general often precludes in-depth structural characterization of the underlying mechanisms of action. Here, we discovered a novel mechanism of Ets1 activation by DNA-bound Runx1 that involves the displacement of entire inhibitory module of Ets1 by EID of Runx1. Moreover, our data revealed that such displacement efficiently counteracts the strong inhibitory effect of Ets1 phosphorylation. This novel mechanism of phosphorylated Ets1 activation by Runx1 partnership appears to be unique. First, unlike the widely used reversible phosphorylation-dependent regulation of transcription factors, 42 it does not require Ets1 dephosphorylation. Second, not every Ets1 cooperative DNA binding can overcome the inhibitory effect of Ets1 phosphorylation. For example, contrary to the Runx1Ets1 partnership, Ets1Ets1 cooperative binding to palindromic Etsbinding sites on stromelysin-1 promoter DNA results in additional stabilization of IRM by intermolecular interactions. 22 However, these Ets1Ets1 interactions are not capable of counteracting the inhibitory effect of phosphorylation, and upon phosphorylation, Ets1 loses its ability to bind the stromelysin-1 promoter. 35 It remains to be seen whether Runx1 is a unique activator of phosphorylated Ets1 or whether a variety of other protein partners (for example, Pax5, AP-1 and USF1) 8 are also capable of activating phosphorylated Ets1.
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